β-ELEMENE - AN OVERVIEW

Oral HDAC inhibitor tucidinostat in clients with relapsed or refractory peripheral T-mobile lymphoma: phase IIb benefitsThe anti-PD1 antibody camrelizumab is utilized with A different epigenetic inhibitor decitabine in R/R HL and nearly seventy one% patients obtained CR (Nie et al., 2019). Wang et al. performed the phase II study to evaluate the pr